|
gptkbp:instanceOf
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:activeMetabolite
|
gptkb:SN-38
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:FDA
1996
|
|
gptkbp:ATCCode
|
L01XX19
|
|
gptkbp:brand
|
gptkb:Camptosar
|
|
gptkbp:CASNumber
|
97682-44-5
|
|
gptkbp:chemicalFormula
|
C33H38N4O6
|
|
gptkbp:contraindication
|
severe bone marrow suppression
hypersensitivity to irinotecan
|
|
gptkbp:discoveredBy
|
gptkb:Yakult_Honsha
|
|
gptkbp:eliminationHalfLife
|
6-12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:foundIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
irinotecan
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
topoisomerase I inhibitor
|
|
gptkbp:metabolism
|
gptkb:carboxylesterase
|
|
gptkbp:molecularWeight
|
586.7 g/mol
|
|
gptkbp:origin
|
semisynthetic derivative of camptothecin
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
neutropenia
|
|
gptkbp:usedFor
|
colorectal cancer
Small Cell Lung Cancer
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
gptkb:camptothecin
|
|
gptkbp:bfsLayer
|
6
|